https://www.selleckchem.com/pr....oducts/tenalisib-rp6
2 ± 12.2 mmol/mol]), P = 0.0001. The percentage of time in hypoglycemia ( less then 70 mg/dL [ less then 3.9 mmol/L]) was lower among rtCGM vs. isCGM participants [4.3% ± 2.8% vs. 6.4% ± 5.3%], P = 0.003). Patients with rtCGM spent less time in clinically significant hypoglycemia ( less then 54 mg/dL [ less then 3.0 mmol/L]) (0.9% ± 1.0% vs. 2.3% ± 2.5%, P less then 0.0001) and more time in target range (70-180 mg/dL [3.9-10 mmol/L]) than isCGM users (67.5% ± 14.8% vs. 57.8% ± 17.0%), P = 0.0002. Conclusions rtCGM was superio
Like
Comment
Share
